Format

Send to

Choose Destination
J Steroid Biochem Mol Biol. 2016 Jan;155(Pt B):252-6. doi: 10.1016/j.jsbmb.2015.04.006. Epub 2015 Apr 9.

Update on the Vitamin D and OmegA-3 trial (VITAL).

Author information

1
Division of Preventive Medicine, Department of Medicine Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue East Boston, MA 02215, United States; Division of Cardiovascular Medicine, Department of Medicine, VA Boston Healthcare System, West Roxbury Campus, 1400 VFW Parkway, West Roxbury, MA 02132, United States. Electronic address: apradhan@partners.org.
2
Division of Preventive Medicine, Department of Medicine Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue East Boston, MA 02215, United States; Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, United States.

Abstract

Despite continued appreciation of the potential role of vitamin D and omega-3 fatty acids in the prevention of cancer and cardiovascular disease (CVD), there remain no completed large-scale, randomized trials of these agents for the primary prevention of cancer or CVD in a population that has not been selected on the basis of elevated risk. The VITamin D and OmegA-3 TriaL (VITAL) is a 2×2 factorial randomized, double-blind, placebo-controlled trial of the benefits and risks of vitamin D (vitamin D3 [cholecalciferol], 2000 IU/d) and marine omega-3 fatty acids (Omacor(®) fish oil, a 1 g/d) in the primary prevention of cancer and CVD among 25,875 men and women, aged ≥50 and ≥55 years, respectively. Randomization began in November 2011 and was completed in March 2014. This report will describe the rationale for the trial and currently available randomized trial data, summarize related ongoing large-scale trials, and provide a brief overview of study design, and an update on randomization milestones, racial/ethnic diversity, biorepository activities, in-depth phenotyping of a subcohort, and ancillary studies.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01169259.

KEYWORDS:

Cancer; Cardiovascular disease; Cholecalciferol; Omega-3 fatty acids; Primary prevention; Randomized controlled trial; Vitamin D

PMID:
25864623
PMCID:
PMC4600007
DOI:
10.1016/j.jsbmb.2015.04.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center